Jason N. Thompson

Array ( [id] => 15290739 [patent_doc_number] => 20190388505 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => METHODS AND COMPOSITIONS FOR IMMUNOMODULATION [patent_app_type] => utility [patent_app_number] => 16/561177 [patent_app_country] => US [patent_app_date] => 2019-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31505 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16561177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15408065 [patent_doc_number] => 20200024354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => BAFF SELECTIVE BINDING COMPOUNDS AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 16/547221 [patent_app_country] => US [patent_app_date] => 2019-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16547221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15574115 [patent_doc_number] => 10577424 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-03-03 [patent_title] => Antibodies binding VISTA and uses thereof [patent_app_type] => utility [patent_app_number] => 16/541193 [patent_app_country] => US [patent_app_date] => 2019-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 8 [patent_no_of_words] => 16178 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16541193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15321095 [patent_doc_number] => 20200000877 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-02 [patent_title] => TREATMENT OF TUMOURS USING PEPTIDE-PROTEIN CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/538516 [patent_app_country] => US [patent_app_date] => 2019-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11699 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16538516 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20329738 [patent_doc_number] => 12460004 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Antibodies that bind CD277 and uses thereof [patent_app_type] => utility [patent_app_number] => 17/267066 [patent_app_country] => US [patent_app_date] => 2019-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 35 [patent_no_of_words] => 32470 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 447 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17267066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15086435 [patent_doc_number] => 20190338028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => CD47-CAR-T CELLS [patent_app_type] => utility [patent_app_number] => 16/521421 [patent_app_country] => US [patent_app_date] => 2019-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6649 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16521421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15496307 [patent_doc_number] => 20200048342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => IMMUNOLOGICAL TREATMENT OF CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY [patent_app_type] => utility [patent_app_number] => 16/519683 [patent_app_country] => US [patent_app_date] => 2019-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8664 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16519683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16770915 [patent_doc_number] => 10982004 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Anti-TLR4 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/517016 [patent_app_country] => US [patent_app_date] => 2019-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 15 [patent_no_of_words] => 29655 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16517016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060151 [patent_doc_number] => 11104738 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Monoclonal antibodies to human FLT3/FLK2 receptor protein [patent_app_type] => utility [patent_app_number] => 16/506764 [patent_app_country] => US [patent_app_date] => 2019-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 17 [patent_no_of_words] => 15037 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16506764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19840172 [patent_doc_number] => 12252541 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Anti-BCMA antibody and use thereof [patent_app_type] => utility [patent_app_number] => 17/053256 [patent_app_country] => US [patent_app_date] => 2019-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 11766 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1282 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17053256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15039177 [patent_doc_number] => 20190330593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => LILRB2 AND NOTCH-MEDIATED EXPANSION OF HEMATOPOIETIC PRECURSOR CELLS [patent_app_type] => utility [patent_app_number] => 16/453515 [patent_app_country] => US [patent_app_date] => 2019-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28861 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16453515 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14963113 [patent_doc_number] => 20190309034 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => NOVEL ANTI-BAFF ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/451333 [patent_app_country] => US [patent_app_date] => 2019-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16451333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18202405 [patent_doc_number] => 11584787 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-21 [patent_title] => Soluble CD33 for treating myelodysplastic syndromes (MDS) [patent_app_type] => utility [patent_app_number] => 16/451525 [patent_app_country] => US [patent_app_date] => 2019-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 78 [patent_no_of_words] => 23341 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16451525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067286 [patent_doc_number] => 20210269501 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => COMPOSITIONS AND METHODS OF NKG2D CHIMERIC ANTIGEN RECEPTOR T CELLS FOR CONTROLLING TRIPLE-NEGATIVE BREAST CANCER [patent_app_type] => utility [patent_app_number] => 17/255108 [patent_app_country] => US [patent_app_date] => 2019-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21981 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17255108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16914014 [patent_doc_number] => 20210187106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => COMBINATION OF LIF INHIBITORS AND PLATINUM-BASED ANTINEOPLASTIC AGENTS FOR USE IN TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/252449 [patent_app_country] => US [patent_app_date] => 2019-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17252449 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16086995 [patent_doc_number] => 20200197484 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => COMPOSITIONS, KITS AND METHODS FOR TREATMENT OF COMPLEMENT-RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 16/442163 [patent_app_country] => US [patent_app_date] => 2019-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34755 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16442163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16870147 [patent_doc_number] => 20210163614 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => APJ ANTIBODY, FUSION PROTEIN THEREOF WITH ELABELA, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/251663 [patent_app_country] => US [patent_app_date] => 2019-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22498 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17251663 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15254231 [patent_doc_number] => 20190375849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 16/434188 [patent_app_country] => US [patent_app_date] => 2019-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52511 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16434188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15209883 [patent_doc_number] => 20190367628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => BINDING MOLECULES AGAINST BCMA AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/426914 [patent_app_country] => US [patent_app_date] => 2019-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 135872 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16426914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16261282 [patent_doc_number] => 10752702 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-25 [patent_title] => Anti-TIE2 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/390459 [patent_app_country] => US [patent_app_date] => 2019-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 17194 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16390459 [rel_patent_id] =>[rel_patent_doc_number] =>)